Expression ofadhesion molecules. RMFI at baseline, 6 and 24 hours after administration of plerixafor 0.24 mg/kg for (A) 2 different mAbs against CD184 (CXCR4), 12G5, and 1D9 (n = 38) and (B) CD62L (L-selectin, n = 24), CD49d (VLA-4, n = 38), and CD123 (IL3RA, n = 38). (C) Migration of PBMCs to CXCL12 (200 ng/mL) compared with no CXCL12 in transwell assay at baseline and 6 hours after administration of plerixafor (n = 10).